Verso Introduces VersoRx™ Pharmaceutical Inserts, Adding to its Specialty Papers Product Line
MEMPHIS, Tenn.--(BUSINESS WIRE)-- Verso Paper Corp. (NYS: VRS) announces the launch of a new pharmaceutical insert grade: VersoRx™. This new product offering, engineered to deliver outstanding print fidelity while providing excellent sheeting and folding performance, is an exciting addition to Verso's growing specialty papers product portfolio.
"Our introduction of VersoRx™ pharmaceutical inserts is a great example of our continued focus in the specialty papers market segment," says Mike Weinhold, Verso's Senior Vice President of Sales, Marketing and Product Development. "By adding the VersoRx™ products to our portfolio, we have enhanced the wide range of product solutions that Verso offers converters, printers, and end-users."
Available in 27#, 30# and 35# basis weights, VersoRx™ pharmaceutical inserts are produced on the No. 1 paper machine at Verso's mill in Bucksport, Maine. "The No. 1 paper machine at Bucksport plays a key role in Verso's plan to diversify its product line and expand in the specialty papers market segment," Weinhold explains. "Thanks to the expertise and ingenuity of our manufacturing team and to strategic investments made at the Bucksport Mill, we are pleased to announce this important, new commercial component of our product diversification plan. The VersoRx™ products are integral to the success of our diversification efforts, both now and in the future," he says.
VersoRx™ is offered certified, upon request, to meet our customers' PEFC (BV-PEFCCOC-US005202-1), SFI®, or FSC® (BV-COC-301978) needs. For more information on VersoRx™ pharmaceutical inserts or other Verso products, please visit versopaper.com or contact Verso at 1-800-258-8852.
Based in Memphis, Tennessee, Verso Paper Corp. is a leading North American producer of coated papers, including coated groundwood and coated freesheet, and specialty products. Verso's paper products are used primarily in media and marketing applications, including magazines, catalogs and commercial printing applications such as high-end advertising brochures, annual reports and direct-mail advertising. Additional information about Verso is available on the Company's website at www.versopaper.com.
In this press release, all statements that are not purely historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by the words "believe," "expect," "anticipate," "project," "plan," "estimate," "intend" and similar expressions. Forward-looking statements are based on currently available business, economic, financial and other information and reflect management's current beliefs, expectations and views with respect to future developments and their potential effects on Verso. Actual results could vary materially depending on risks and uncertainties that may affect Verso and its business. For a discussion of such risks and uncertainties, please refer to Verso's filings with the Securities and Exchange Commission. Verso assumes no obligation to update any forward-looking statement made in this press release to reflect subsequent events or circumstances or actual outcomes.
KEYWORDS: United States North America Tennessee
The article Verso Introduces VersoRx™ Pharmaceutical Inserts, Adding to its Specialty Papers Product Line originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.